Variable selection k nearest neighbor QSAR modeling approach was applied to a data set of 80 3-arylisoquinolines exhibiting cytotoxicity against human lung tumor cell line (A-549). All compounds were characterized with molecular topology descriptors calculated with the MolconnZ program. Seven compounds were randomly selected from the original dataset and used as an external validation set. The remaining subset of 73 compounds was divided into multiple training (56 to 61 compounds) and test (17 to 12 compounds) sets using a chemical diversity sampling method developed in this group. Highly predictive models characterized by the leave-one out cross-validated R 2 (q 2 ) values greater than 0.8 for the training sets and R 2 values greater than 0.7 for the test sets have been obtained. The robustness of models was confirmed by the Y-randomization test: all models built using training sets with randomly shuffled activities were characterized by low q 2 ≤ 0.26 and R 2 ≤ 0.22 for training and test sets, respectively. Twelve best models (with the highest values of both q 2 and R
Introduction
A large number of anticancer chemotherapeutic agents have been developed over the last decades. Still, there is no doubt that further research into the design of novel anticancer compounds with low toxicity and higher selectivity is needed.
1 Isoquinoline analogues of natural or synthetic antitumor agents have attracted considerable interest as potent anticancer agents. It has been established that they act via the inhibition of topoisomerases I (topo I) or II (topo II), or as DNA intercalators.
2
The synthesis, biological evaluation, and 3D-QSAR studies of 3-arylisoquinolines were carried out in one of our laboratories previoulsy. 3 These compounds have been shown to be highly cytotoxic against several types of human tumor cells. Interestingly, some (but not all) of these compounds also showed topo I inhibitory activity.
4 Indenoisoquinoline derivatives were thoroughly investigated by the Cushman group and were also reported to have topo I inhibitory activity.
5 Although these studies have identified important structural patterns within isoquinolines responsible for their cytotoxicity, it proved to be difficult to rationalize the relationships between their topo I inhibitory activity and cytotoxicity. In the previous paper, a hypothetical pharmacophore model of 3-arylisoquinolines active against human lung tumor cell (A-549) was proposed based on results of the Comparative Molecular Field Analysis (CoMFA).
6 Subsequent research focused on introducing the various amines in the C-1 position replacing N-methylpiperazine in 3-arylisoquinolines and conducting additional studies towards the antitumor cytotoxicity and topo I inhibition activity of isoquinolinamines. As a result, water-soluble 3-arylisoquinolinamines were identified as potent cytotoxic agents.
7
The important insights into rational design of novel potent comounds could be obtained by studying the relationships between structure and cytotoxicity of 3-arylisoquinoline compounds, which could be achieved by using reliable and robust QSAR approaches. Over the last two decades many QSAR approaches have been developed. Based on the type of descriptors used, they can be divided into those utilizing physicochemical properties of molecules, two-dimensional (2D) and three-dimensional (3D) QSAR approaches.
One of the most popular 3D-QSAR methods, CoMFA developed in mid-eighties 8 and other CoMFA-like methods (some of them are discussed in references 9 require spatial alignment of molecules. CoMFA and many other 3D-QSAR methods have several shortcomings. 10 In many cases, it is impossible to precisely define a pharmacophore model (i.e., specific and characteristic 3D arrangements of chemical functional groups responsible for biological activity.
11 If all molecules in a dataset are flexible, their unique structural alignment is impossible. 18 This can lead to non-optimal alignment of ligands, and eventually can introduce errors in QSAR analysis. On the other hand, QSAR analysis based on descriptors calculated using mole-cular graphs, i.e. structural formulas of compounds (2D-QSAR) provides an appealing alternative to 3D-QSAR since the former methods neither require conformational search nor structural alignment, are faster and easier to implement in an automated fashion, and are typically characterized by models with the same or better statistical significance and predictive power. These features also make 2D-QSAR approaches easily adaptable to the task of database searching, or virtual screening.
19
We have developed several stochastic variable selection QSAR procedures including genetic algorithm or simulated annealing partial least squares (GA/SA-PLS) 20 and k-nearestneighbor (kNN) QSAR. 10, 21 As opposed to the conventional 3D-pharmacophore, we have defined a descriptor pharmacophore as a subset of molecular descriptors that give rise to the most statistically significant QSAR models.
19 Typically, we use these methods with multiple descriptors derived from 2D molecular topology, which eliminates the conformational and alignment ambiguities inherent in most 3D-QSAR approaches. Stochastic optimization algorithms such as GA or SA are used to develop a robust QSAR model that is characterized by the highest value of cross validated R 2 (q 2 ). By default, the descriptor pharmacophore corresponds to a variable selection model with a local maximum of q 2 . These methods are computationally efficient and automated and they have been used to generate predictive models that are comparable to, or better than, those obtained with CoMFA.
22
In this paper, we have applied the kNN QSAR approach and rigorous model validation procedures to a dataset of 80 antitumor 3-arylisoquinolines that were synthesized and evaluated previously. 6 Our results demonstrate the effectiveness of the kNN QSAR approach and provide rationale for further design and synthesis of novel potent antitumor agents.
Methods
Cytotoxicity Measurements. The structures of 80 compounds used for building kNN models are shown in Schemes 1 6 Scheme 1. Structure of the training set compounds (1).
Scheme 2. Structure of the training set compounds (2).
Development of kNN QSAR Models for 3-Arylisoquinoline Antitumor Agents Bull. Korean Chem. Soc. 2011 , Vol. 32, No. 7 2399 and 2. 4a In Table 1 , the cytotoxicities of 57 compounds (1-9) are listed and those for the remaining 23 compounds (10) (11) (12) (13) (14) (15) (16) are listed in Table 2 . Cytotoxicity (IC 50 value) was obtained by the National Cancer Institute protocol based on the sulforhodamine B (SRB) method. 23 In brief, tumor cells were cultured to keep logarithmic growth by changing the medium 24 h before cytotoxicity assays. On the day of the assay, the cells were harvested by trysinization, counted, diluted in media and added to 96-well plates. The concentration of tumor cells (A-549) used was 1 × 10 4 cells per ml. The cells were then preincubated for 24 h in a 5% CO 2 incubator at 37 o C. The compounds dissolved in DMSO were added to the wells in six 2-fold dilutions starting from the highest concentrations, and incubated for 48 h in a 5% CO 2 incubator at 37 o C. The final DMSO concentration was 0.05%. At the termination of the incubation, the culture medium in each well was removed, and the cells were fixed with cold 10% trichloroacetic acid (TCA) for 1 h at room temperature. The microplates were washed, dried, and stained with 0.4% SRB in 1% acetic acid for 30 minutes at room temperature. The cells were washed again and the bound stain was solubilized with 10 mM Tris base solution (pH 10.5), and the absorbances were measured spectrophotometrically at 520 nm on a microtiter plate reader (Molecular Devices, Sunnyvale, CA). The data was transformed into Lotus-123 format and survival fractions were calculated by regression analysis (plotting the cell viability versus the concentration of the test compound). The IC 50 ) and the correlation coefficient R 2 between the predicted and observed activities for a test set.
9c, 35 Our group has advocated repeatedly the importance of the external validation that requires an independent test set for the validation of the model. 36 We have implemented a rational approach based on a sphereexclusion algorithm for dividing the dataset into multiple training and test sets for internal and external validation, respectively.
20b,36 If possible, validation requirements must include not only test sets, but also a second external test set (an independent validation set) for the additional validation.
37
The independent validation test set should be selected randomly from the entire dataset in the beginning of the calculations. It should be used to simulate the use of QSAR models for new compounds resulting from ongoing experimental projects.
The dataset of 80 compounds was divided into three subsets (Figure 1) . The first subset of seven compounds was selected randomly. The remaining 73 compounds were divided rationally into multiple training and test sets with the diversity sampling Sphere Exclusion (SE) algorithm. The Otherwise let m be the number of probe spheres constructed and n be the number of remaining compounds. Let d ij (i=1,..., m; j=1,..., n) be the distances between the remaining compounds and the probe sphere centers. Select a compound corresponding to the lowest d ij value and go to step (ii). The training sets were used to build models and the test sets were used for model testing. The independent set of seven compounds was used for an additional external validation.
k-Nearest Neighbor (kNN) QSAR with Variable Selection. We have described this approach elsewhere 21 and present here only a brief overview. kNN QSAR is a stochastic variable selection procedure where the model optimization is driven by simulated annealing, as illustrated in Figure 3 . The kNN procedure is aimed at the development of the model with the highest leave-one-out (LOO) cross-validated correlation coefficient R 2 (q 2 ) for the training set.
( 1) where N and are the number of compounds and the average observed activity of the training set, respectively, and y i and are the observed and predicted activities of the i-th compound, respectively.
The procedure starts with the random selection of a predefined number of descriptors from all descriptors. Activity of a compound y i excluded in the LOO cross-validation procedure is predicted as the weighted average of activities of its nearest neighbors according to the following formula:
(2) where d ij are distances between the i-th compound and its k nearest neighbors ( j=1,..., k). The optimal number of nearest neighbors that yields the highest q 2 value is defined as part of the LOO cross-validation process as well. After each run of the LOO procedure, a predefined number of descriptors are randomly changed, and the new value of q 2 is calculated. If q 2 (new) > q 2 (old), the new set of descriptors is accepted. If q 2 (new) ≤ q 2 (old), the new set of descriptors is accepted with probability p = exp(q 2 (new) − q 2 (old))/T, and rejected with probability (1−p), where T is a simulated annealing parameter, "temperature. During the process, T is decreasing until the predefined value, and when this value is achieved the optimization process is terminated.
For each of the six splits into the training and test sets, the number of descriptors selected in the kNN-QSAR procedure varied from 6 to 40 with step 2 (18 values). The number of models built for each pair (split, number of descriptors selected) was 10. Thus, the total number of models was 10 × 6 × 18 = 1080.
Model Validation and the Applicability Domain. QSAR models were initially validated using test sets. The models were considered acceptable if the following conditions were satisfied. (Figure 3 ) has been successfully used in our laboratory for many datasets.
21,38
The activity of the test set compounds was predicted only if these compounds were within the applicability domain of the respective training set models. We define this domain 36a as a threshold distance in multidimensional descriptor space between a test set compound and its closest nearest neighbor in the training set. If the distance is beyond the threshold, the prediction is not made since it is considered unreliable. This threshold distance is calculated as D 
Z*VAR, where <D
2 nn > is the squared mean distance between all training set compounds and their k nearest neighbors in the descriptor subspace defined by the descriptors selected (descriptor pharmacophore), VAR is the variance of D nn , and Z is a user-defined parameter (in this studies we used Z=0.5).
Training set models that passed our validation criteria (i)-(iv) were used for the prediction of the independent validation set of seven randomly selected compounds.
For our ongoing experimental investigations, we rely on the consensus prediction, which implies averaging the binding affinities of each compound predicted by individual models with best statistics. Y-randomization Test. This is a generally used technique to establish, if the model is robust, and to exclude the possibility of overfitting and chance correlation. 39 The Yrandomization test was carried out after dividing the dataset into training and test sets. The robustness of the models was examined by comparing the statistics of models developed for the original dataset with those obtained by using randomized antitumor activity values of the training set. It is expected that the latter models should have low q 2 values for the training set and low R 2 values for the test set. The Yrandomization test was repeated five times for each splitting of the dataset into training and test sets.
Results and Discussion
We now discuss the results of kNN QSAR modeling of 80 3-arylisoquinolines in terms of the optimized q 2 values, variable selection, observed vs. predicted activities, statistical significance and experimental validation.
Development of validated kNN QSAR Models. To establish reliability and the true predictive power of QSAR models, it is necessary to demonstrate that they can accurately predict activities of compounds of external test sets. Generally, we accept models with q 2 values for the training set greater than 0.5 and R 2 values for predicted vs. observed activities of the test set compounds greater than 0.6; other characteristics should satisfy conditions described in the Methods section. From the entire dataset of 80 compounds a subset of seven compounds was randomly excluded as an independent validation set and the remaining 73 compounds were divided into six different training and test sets containing 61 and 12, 57 and 16, 60 and 13, 59 and 14, 56 and 17, and 58 and 15 compounds in training and test sets, respectively (Table 3) . The 12 best models were selected from multiple kNN models. All these models showed good correlation between q 2 (0.81-0.88) and R 2 (0.70-0.86). The models with the highest predictive power were obtained for the test sets with 12 to 17 compounds, with the optimal number of descriptors ranging between 10 and 28.
To evaluate the external predictive power of our models, the predicted activities of the seven compounds set aside as external validation set were compared with their observed activities. We used all models that passed our validation criteria to calculate the predicted activity. The results clearly demonstrate the high prediction accuracy with R 2 values ranging from 0.71 to 0.93 (Table 4) . Model 5 showed best R 2 2 : the coefficients of determination for regressions through the origin between predicted and observed, and observed and predicted activities of the test set. (0.93), R 01 2 (0.91) and R 02 2 (0.93). As discussed in Methods, we also performed the Yrandomization test. Activities of the training set compounds were randomized and all the calculations were repeated five times. The highest training set q 2 was 0.26 and the highest test set R 2 was 0.22. These results demonstrate that the models developed for the actual dataset were robust, and their high q 2 and R 2 values could not be explained by overfitting or chance correlation.
In summary, the results of activity prediction for compounds in datasets successfully paralleled those obtained in model building and validation using internal training and test sets. This observation agrees with our general experience in developing QSAR models with the confirmed predictive power. It emphasizes that before attempting to predict target properties of untested compounds one should exhaustively validate QSAR models developed for the training sets both internally and externally such that only models that pass rigorous validation criteria should be used for the prediction. It was interesting to analyze the performance of QSAR models with respect to distinctive chemical modifications implied in the design of the external set of new compounds.
Conclusions
In this study, we have developed and thoroughly validated QSAR models for a series of 3-arylisoquinoline compounds that have been studied as potential anticancer agents. We have demonstrated that the validated kNN QSAR modeling workflow was successful in generating models with high internal and external accuracy. These models can be further exploited for the design and discovery of new, potent antitumor agents by the means of virtual screening of available chemical databases as discussed in the recent review.
40
These virtual screening studies towards the identification and subsequent testing of novel compounds predicted to have high antitumor activity are in progress. Table 5 . Predicted and observed pIC50 values for the external test set compounds using 12 best models (see Table 3 
